Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Will Use Yervoy’s Successful Launch As Model For Opdivo

This article was originally published in The Pink Sheet Daily

Executive Summary

The big pharma posted strong results in the third quarter for its oncology franchise, but looks to its future in cancer immunotherapy to bring about growth post-patent losses.

You may also be interested in...



Emerging Markets Earnings: BMS Eyes HCV In Japan, China HIV Sales Slow

Bristol-Myers Squibb provides few insights into emerging markets earnings, though it fills in some color on HCV in Japan and China HIV sales.

Merck’s Keytruda Opens Door, But Combination Trials Could Unlock Efficacy

FDA’s approval of Merck’s anti-PD-1 drug pembrolizumab in melanoma marks a major milestone for oncology and industry’s immune checkpoint efforts. But with an overall response rate in labeling of 24%, there’s still room for improvement with combinations and use in earlier lines of therapy.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel